6-pyrimidin-isoindole derivative as ERK1/2 inhibitor
US11142518B2 · kind B2 · utility
2Cited by
3References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 20, 2018 |
| Grant date | Oct 12, 2021 |
| Priority date | — |
| Expiry date | Jun 21, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.